Although multiple sclerosis (MS) is considered to be a CD4, Th17-mediated autoimmune
disease, supportive evidence is perhaps circumstantial, often based on animal studies, and …

Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous
system that results in demyelination of axons, inefficient signal transmission and reduced …

In multiple sclerosis (MS), lymphocyte—in particular B cell—transit between the central
nervous system (CNS) and periphery may contribute to the maintenance of active disease …

The efficacy of B cell depletion therapy in multiple sclerosis indicates their central
pathogenic role in disease pathogenesis. The B lymphotropic EBV is a major risk factor in …

B cell-directed therapies are promising treatments for autoimmune disorders. Besides
targeting CD20, newer B cell-directed therapies are in development that target other B cell …

2 mononuclear cells (Hoover et al., 2008), which is consistent with the sharp reduction in
relapses and MRI activity observed in trials for MS (Hauser et al., 2017). If anti-CD20 …

Selective B-cell depletion with anti-CD20 therapy is a promising novel treatment option for
patients with refractory autoimmune disease. The anti-CD20 antibody, rituximab, is the first …

Abstract Anti-CD20-mediated B-cell depletion effectively reduces acute multiple sclerosis
(MS) flares. Recent data shows that antibody-mediated extinction of B cells as a lasting …

B cell hyperactivity is a hallmark of the complex autoimmune disease systemic lupus
erythematosus (SLE), which has justified drug development focusing on B cell altering …

Background and Objectives Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that
establishes lifelong latency in memory B cells and has been identified as a major risk factor …